Antiviral activity of brincidofovir on parvovirus B19.

Antiviral Agents / pharmacology Cells, Cultured Cytosine / analogs & derivatives Erythroid Precursor Cells / virology Humans Organophosphonates / pharmacology Parvovirus B19, Human / drug effects Virus Replication / drug effects
Brincidofovir Erythroid progenitor cells Parvovirus B19 Replication inhibition UT7/EpoS1 cells

Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 09 2018
revised: 30 10 2018
accepted: 06 12 2018
pubmed: 12 12 2018
medline: 11 2 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

Parvovirus B19 (B19V), a single-stranded DNA virus in the family Parvoviridae, is a human pathogenic virus responsible for a wide range of clinical manifestations. Currently there is no approved antiviral therapy for parvovirus infection. The acyclic nucleoside phosphonate cidofovir (CDV) has been demonstrated to inhibit replication of B19V in vitro. The aim of the present study was to evaluate whether brincidofovir (BCV), a novel lipid conjugate of CDV, could also inhibit B19V replication. Experiments were carried out in erythroid progenitor cells (EPCs) and UT7/EpoS1 cells, infected with B19V and cultured in the presence of different concentrations of BCV and CDV for comparison. The dynamics of viral replication was evaluated by a qPCR-based assay and the extent of inhibition of viral replication exerted by the compounds determined, along with the effect of the compounds on cell viability and cell proliferation rates. Results confirmed that BCV showed significantly higher antiviral activity against B19V compared to CDV in both cell-based systems. For BCV, the calculated EC

Identifiants

DOI: 10.1016/j.antiviral.2018.12.003 PMID: 30529090
pubmed: 30529090
pii: S0166-3542(18)30539-4
doi: 10.1016/j.antiviral.2018.12.003
pii:
doi:

Substances chimiques

Antiviral Agents 0
Organophosphonates 0
brincidofovir 6794O900AX
Cytosine 8J337D1HZY

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-29

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Gloria Bua (G)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Ilaria Conti (I)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Elisabetta Manaresi (E)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Phiroze Sethna (P)

Chimerix, Durham, NC, USA.

Scott Foster (S)

Chimerix, Durham, NC, USA.

Francesca Bonvicini (F)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Giorgio Gallinella (G)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; S.Orsola-Malpighi Hospital - Microbiology, University of Bologna, Via Massarenti, 9, I-40138, Bologna, Italy. Electronic address: giorgio.gallinella@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Cellules › Cellules cultivées › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Cytosine › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › Cellules souches hématopoïétiques › Progéniteurs myéloïdes › Progéniteurs érythroïdes et mégacaryocytaires › Précurseurs érythroïdes › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphonates › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Virus › Virus à ADN › Parvoviridae › Parvovirinae › Erythrovirus › Parvovirus humain B19 › Antiviral activity of brincidofovir on parvovirus B19.
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Antiviral activity of brincidofovir on parvovirus B19.